CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential

Although early stage ovarian cancer can be effectively treated with surgery and chemotherapy, the majority of cases present with advanced disease, which remains essentially incurable. Unfortunately, little is known about the genes important for the development and progression of this disease. In thi...

Descripción completa

Detalles Bibliográficos
Autores: Manzano, R.G. (Ramón G.)|||/items/51fae546-90ba-4ba0-855c-dc1143662604, Montuenga-Badia, L.M. (Luis M.)|||/items/4c999705-b2c9-45ac-ba13-3f18594ae596, Dayton, M. (M.)|||/items/4b929380-3551-4105-aae4-e404c8de325a, Dent, P. (P.)|||/items/db82a58c-618e-4312-b077-98b08286d3bb, Kinoshita, I. (Ichiro)|||/items/7445386e-cfa4-4ab5-92ee-3ecf9c6bc118, Vicent-Cambra, S. (Silvestre)|||/items/20c60fd9-edba-4dba-942c-3669eb079816, Gardner, G.J. (Ginger J.)|||/items/69303766-04e6-444d-9c76-b579aee15062, Nguyen, P. (PhuongMai)|||/items/b4e5777b-c32a-4e4c-aaa2-276d03df15d1, Choi, Y.H. (Yung-Hyun)|||/items/22959b5b-3c34-4b8e-947f-6d2460fe794a, Trepel, J. (Jane)|||/items/1ee593ac-2c68-4f4d-9480-6121249f9ce4, Auersperg, N. (N.)|||/items/1d6fa4ff-34b6-4ba8-8cbc-e554efb8be8a, Birrer, M.J. (Michael J.)|||/items/0fd36514-78ea-43e9-87bf-3ca6f72a44a9
Tipo de recurso: artículo
Fecha de publicación:2002
País:España
Institución:Universidad de Navarra
Repositorio:Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:inglés
OAI Identifier:oai:dadun.unav.edu:10171/20183
Acceso en línea:https://hdl.handle.net/10171/20183
Access Level:acceso abierto
Palabra clave:MKP-1
Ovarian
Cancer
Phosphatases
Growth
Motility
id ES_f7a3ea93f60e4cdde40efe4ab7fd3c66
oai_identifier_str oai:dadun.unav.edu:10171/20183
network_acronym_str ES
network_name_str España
repository_id_str
spelling CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potentialManzano, R.G. (Ramón G.)|||/items/51fae546-90ba-4ba0-855c-dc1143662604Montuenga-Badia, L.M. (Luis M.)|||/items/4c999705-b2c9-45ac-ba13-3f18594ae596Dayton, M. (M.)|||/items/4b929380-3551-4105-aae4-e404c8de325aDent, P. (P.)|||/items/db82a58c-618e-4312-b077-98b08286d3bbKinoshita, I. (Ichiro)|||/items/7445386e-cfa4-4ab5-92ee-3ecf9c6bc118Vicent-Cambra, S. (Silvestre)|||/items/20c60fd9-edba-4dba-942c-3669eb079816Gardner, G.J. (Ginger J.)|||/items/69303766-04e6-444d-9c76-b579aee15062Nguyen, P. (PhuongMai)|||/items/b4e5777b-c32a-4e4c-aaa2-276d03df15d1Choi, Y.H. (Yung-Hyun)|||/items/22959b5b-3c34-4b8e-947f-6d2460fe794aTrepel, J. (Jane)|||/items/1ee593ac-2c68-4f4d-9480-6121249f9ce4Auersperg, N. (N.)|||/items/1d6fa4ff-34b6-4ba8-8cbc-e554efb8be8aBirrer, M.J. (Michael J.)|||/items/0fd36514-78ea-43e9-87bf-3ca6f72a44a9MKP-1OvarianCancerPhosphatasesGrowthMotilityAlthough early stage ovarian cancer can be effectively treated with surgery and chemotherapy, the majority of cases present with advanced disease, which remains essentially incurable. Unfortunately, little is known about the genes important for the development and progression of this disease. In this study, the expression of 68 phosphatases was determined in immortalized ovarian epithelial cells (IOSE) and compared to ovarian cancer cell lines. CL100, a dual specificity phosphatase, displayed 10-25-fold higher expression in normal compared to malignant ovarian cell lines. Immunohistochemical staining of normal ovaries and 68 ovarian cancer specimens confirmed this differential expression. Re-expression of CL100 in ovarian cancer cells decreased adherent and non-adherent cell growth and induced phenotypic changes including loss of filopodia and lamellipodia with an associated decrease in cell motility. Induced expression of CL100 in ovarian cancer cells suppressed intraperitoneal tumor growth in nude mice. These results show for the first time that CL100 expression is altered in human ovarian cancer, that CL100 expression changes cell morphology and motility, and that it suppresses intraperitoneal growth of human ovarian epithelial cancer. These data suggest that down-regulation of CL100 may play a role in the progression of human ovarian cancer.Nature Publishing GroupDadun. Depósito Académico Digital Universidad de Navarra20112011-12-1220022002-01-0120022002-01-01journal articlehttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10171/20183reponame:Dadun. Depósito Académico Digital de la Universidad de Navarrainstname:Universidad de NavarraInglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:dadun.unav.edu:10171/201832026-06-21T12:47:57Z
dc.title.none.fl_str_mv CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential
title CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential
spellingShingle CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential
Manzano, R.G. (Ramón G.)|||/items/51fae546-90ba-4ba0-855c-dc1143662604
MKP-1
Ovarian
Cancer
Phosphatases
Growth
Motility
title_short CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential
title_full CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential
title_fullStr CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential
title_full_unstemmed CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential
title_sort CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential
dc.creator.none.fl_str_mv Manzano, R.G. (Ramón G.)|||/items/51fae546-90ba-4ba0-855c-dc1143662604
Montuenga-Badia, L.M. (Luis M.)|||/items/4c999705-b2c9-45ac-ba13-3f18594ae596
Dayton, M. (M.)|||/items/4b929380-3551-4105-aae4-e404c8de325a
Dent, P. (P.)|||/items/db82a58c-618e-4312-b077-98b08286d3bb
Kinoshita, I. (Ichiro)|||/items/7445386e-cfa4-4ab5-92ee-3ecf9c6bc118
Vicent-Cambra, S. (Silvestre)|||/items/20c60fd9-edba-4dba-942c-3669eb079816
Gardner, G.J. (Ginger J.)|||/items/69303766-04e6-444d-9c76-b579aee15062
Nguyen, P. (PhuongMai)|||/items/b4e5777b-c32a-4e4c-aaa2-276d03df15d1
Choi, Y.H. (Yung-Hyun)|||/items/22959b5b-3c34-4b8e-947f-6d2460fe794a
Trepel, J. (Jane)|||/items/1ee593ac-2c68-4f4d-9480-6121249f9ce4
Auersperg, N. (N.)|||/items/1d6fa4ff-34b6-4ba8-8cbc-e554efb8be8a
Birrer, M.J. (Michael J.)|||/items/0fd36514-78ea-43e9-87bf-3ca6f72a44a9
author Manzano, R.G. (Ramón G.)|||/items/51fae546-90ba-4ba0-855c-dc1143662604
author_facet Manzano, R.G. (Ramón G.)|||/items/51fae546-90ba-4ba0-855c-dc1143662604
Montuenga-Badia, L.M. (Luis M.)|||/items/4c999705-b2c9-45ac-ba13-3f18594ae596
Dayton, M. (M.)|||/items/4b929380-3551-4105-aae4-e404c8de325a
Dent, P. (P.)|||/items/db82a58c-618e-4312-b077-98b08286d3bb
Kinoshita, I. (Ichiro)|||/items/7445386e-cfa4-4ab5-92ee-3ecf9c6bc118
Vicent-Cambra, S. (Silvestre)|||/items/20c60fd9-edba-4dba-942c-3669eb079816
Gardner, G.J. (Ginger J.)|||/items/69303766-04e6-444d-9c76-b579aee15062
Nguyen, P. (PhuongMai)|||/items/b4e5777b-c32a-4e4c-aaa2-276d03df15d1
Choi, Y.H. (Yung-Hyun)|||/items/22959b5b-3c34-4b8e-947f-6d2460fe794a
Trepel, J. (Jane)|||/items/1ee593ac-2c68-4f4d-9480-6121249f9ce4
Auersperg, N. (N.)|||/items/1d6fa4ff-34b6-4ba8-8cbc-e554efb8be8a
Birrer, M.J. (Michael J.)|||/items/0fd36514-78ea-43e9-87bf-3ca6f72a44a9
author_role author
author2 Montuenga-Badia, L.M. (Luis M.)|||/items/4c999705-b2c9-45ac-ba13-3f18594ae596
Dayton, M. (M.)|||/items/4b929380-3551-4105-aae4-e404c8de325a
Dent, P. (P.)|||/items/db82a58c-618e-4312-b077-98b08286d3bb
Kinoshita, I. (Ichiro)|||/items/7445386e-cfa4-4ab5-92ee-3ecf9c6bc118
Vicent-Cambra, S. (Silvestre)|||/items/20c60fd9-edba-4dba-942c-3669eb079816
Gardner, G.J. (Ginger J.)|||/items/69303766-04e6-444d-9c76-b579aee15062
Nguyen, P. (PhuongMai)|||/items/b4e5777b-c32a-4e4c-aaa2-276d03df15d1
Choi, Y.H. (Yung-Hyun)|||/items/22959b5b-3c34-4b8e-947f-6d2460fe794a
Trepel, J. (Jane)|||/items/1ee593ac-2c68-4f4d-9480-6121249f9ce4
Auersperg, N. (N.)|||/items/1d6fa4ff-34b6-4ba8-8cbc-e554efb8be8a
Birrer, M.J. (Michael J.)|||/items/0fd36514-78ea-43e9-87bf-3ca6f72a44a9
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Dadun. Depósito Académico Digital Universidad de Navarra
dc.subject.none.fl_str_mv MKP-1
Ovarian
Cancer
Phosphatases
Growth
Motility
topic MKP-1
Ovarian
Cancer
Phosphatases
Growth
Motility
description Although early stage ovarian cancer can be effectively treated with surgery and chemotherapy, the majority of cases present with advanced disease, which remains essentially incurable. Unfortunately, little is known about the genes important for the development and progression of this disease. In this study, the expression of 68 phosphatases was determined in immortalized ovarian epithelial cells (IOSE) and compared to ovarian cancer cell lines. CL100, a dual specificity phosphatase, displayed 10-25-fold higher expression in normal compared to malignant ovarian cell lines. Immunohistochemical staining of normal ovaries and 68 ovarian cancer specimens confirmed this differential expression. Re-expression of CL100 in ovarian cancer cells decreased adherent and non-adherent cell growth and induced phenotypic changes including loss of filopodia and lamellipodia with an associated decrease in cell motility. Induced expression of CL100 in ovarian cancer cells suppressed intraperitoneal tumor growth in nude mice. These results show for the first time that CL100 expression is altered in human ovarian cancer, that CL100 expression changes cell morphology and motility, and that it suppresses intraperitoneal growth of human ovarian epithelial cancer. These data suggest that down-regulation of CL100 may play a role in the progression of human ovarian cancer.
publishDate 2002
dc.date.none.fl_str_mv 2002
2002-01-01
2002
2002-01-01
2011
2011-12-12
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/10171/20183
url https://hdl.handle.net/10171/20183
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Nature Publishing Group
publisher.none.fl_str_mv Nature Publishing Group
dc.source.none.fl_str_mv reponame:Dadun. Depósito Académico Digital de la Universidad de Navarra
instname:Universidad de Navarra
instname_str Universidad de Navarra
reponame_str Dadun. Depósito Académico Digital de la Universidad de Navarra
collection Dadun. Depósito Académico Digital de la Universidad de Navarra
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869424901728763904
score 15.301629